Journal articleCancer Res2023
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
- Journal
- Cancer Res
- Published
- 1 January 2023
- Citations
- 146
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 11
- Targeting CDK4/6 for pancreatic cancer treatment F32CA221005↗
- Defining the contributions of WT RAS in RAS-mutant lung cancer F32CA232529↗
- Defining the roles of ERK MAPK in driving KRAS-mutant pancreatic cancer growth. F32CA239328↗
- Project 3: Mechanisms and therapeutic targeting of NRAS in melanoma P01CA203657↗
- Project 1: Overcoming Tumor-Induced Immune Suppression to Improve Responses to Immunotherapy P50CA196510↗
- SToP Cancer SPORE: Administrative Core A P50CA257911↗
- Biological Activity of Ras Oncogenes R01CA042978↗
- Mechanisms of PAK1 activation, signaling and tumor resistance R01CA175747↗
- Targeting undruggable RAS for cancer treatment R35CA232113↗
- Mechanistic dissection and inhibitor targeting of autophagy in RAS driven cancers R37CA251877↗
- Identification of synthetic lethal interactors in pancreatic cancer U01CA199235↗